



AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Phone: 0172-5020758-69 Website: www.ajoonibiotech.com

E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

Date: 03/01/2025

To,
National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East), Mumbai – 400 051

Company Symbol: AJOONI,
ISIN: INE820Y01021

Sub: Outcome of Board Meeting held on February 03, 2024 under Regulation 30 of the SEBI (LODR) Regulations, 2015.

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company in its meeting held on January 03, 2025 at its registered office at D-118, Industrial Area Phase-7, Mohali, Mohali, Punjab, India, 160059, have inter-alia discussed, considered and approved the following:

1. The Board of Directors of the Company has decided to Alter the clause 7 sub clause 'i.' of the Articles of Association of the Company by inserting the new article to empower the Company for the said further issue of securities may be made in any manner whatsoever as the Board may determine including by way of preferential offer or private placement.
2. The Board of Directors of the Company has decided to increase the Authorized Share Capital from Rs. 40,00,00,000 (Rupees Forty Crores Only) divided into 20,00,00,000 (Twenty Crores) Equity Shares of Rs. 2/- (Rupees Two Only) each to Rs. 50,00,00,000/- (Rupees Fifty Crores) divided into 25,00,00,000 (Twenty-Five Crores) Equity Shares of having face value of Rs. 2/- (Rupees Two Only) ranking *pari passu* with the existing Equity Shares of the Company.
3. Issue, offer and allot upto 5,00,00,000 (Five Crores) convertible warrants ('Warrants'), each carrying a right exercisable by the Warrant Holder to subscribe to one Equity Share per Warrant, at a price of Rs. 9/- (Rupees Nine Only) (Warrant Issue Price) per Warrant aggregating to Rs. 45,00,00,000/- (Rupees Forty Five Crores Only) to the Promoters and Non-Promoter categories of persons at the price as determined in accordance with the provision of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 as amended from time to time, subject to the approval of members. The conversion can be exercised at any time during the period of 18 months from the date of allotment of Warrants on such terms and conditions as applicable. The details as required under the SEBI LODR read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 with respect to the proposed preferential issue for Equity Shares are given in Annexure A.
4. Considered and approved the appointment of Mr. Ishtneet Bhatia (DIN: 10440990) as an Additional Director (Independent- Non-Executive) of the company. Brief profile of Mr. Ishtneet Bhatia is given in Annexure B.
5. Considered and approved the Notice of Extra Ordinary General Meeting (EGM) of the Members of the Company scheduled to be held on Monday, February 03, 2025 at 11:30 A.M. through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM").



AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Phone: 0172-5020758-69 Website: www.ajoonibiotech.com

E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

6. Appointment of M/s. M.R. Chechi & Associates, Company Secretaries, Chandigarh as scrutinizer for scrutinizing e-voting of EGM;
7. The relevant date is 03rd January 2024 to consider the proposed preferential issue in accordance the regulations issued by Securities Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended from time to time.
8. Valuation report from Mr. Bhavesh M Rathod, Chartered Accountants (An Independent Registered Valuer) to consider the proposed preferential issue for determining the price in accordance the regulations issued by Securities Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended from time to time.

The Board Meeting commenced at 03.00 P.M. and concluded at 05.00 P.M.

Copies of the EGM Notice will be circulated to Stock Exchanges and the Members through electronic mode and will also be available on the Company's website www.ajoonibiotech.com in due course.

This is for your information and record.

Thanking you,
Yours Faithfully,

For Ajooni Biotech Limited

Swati Vijan
Company Secretary
A39179



AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Phone: 0172-5020758-69 Website: www.ajoonibiotech.com

E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

ANNEXURE A

DISCLOSURE AS PER SEBI (LODR) REGULATIONS, 2015 IS GIVEN BELOW:

S. No.	PARTICULARS	DETAILS
1.	Type of securities proposed to be issued	Convertible Warrants
2.	Type of issuance	Preferential Issue under Chapter V of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018
3.	Total number of securities proposed to be issued	Convertible Warrants: 5,00,00,000 (Detailed list is mentioned hereunder)
4.	Total amount for which the securities will be issued	Convertible Warrants: Rs. 45,00,00,000/-
5.	<p>Post allotment of securities- outcome of the subscription, issue price/ allotted price (in case of convertibles), number of investors</p> <p>In case of convertibles – intimation on conversion of securities or on the lapse of the tenure of the instrument</p>	<ul style="list-style-type: none"> ➤ Issue price of the Convertible Warrants is Rs. 9/- each. The issue price is not lower than the floor price determined in accordance with the Regulation 164 & 166A of Chapter V of SEBI ICDR Regulations. Minimum 25% of the price of the Warrant would be payable upfront at the time of application and the balance 75% shall be payable at the time of conversion of the warrants into Equity Shares of the Company. ➤ Total Number of Investors: 1 for Convertible Warrants ➤ Conversion ratio of each Convertible Warrant: 1:1 <p>Each Warrant can be converted into 1 (One) Equity Share of the Company and conversion can be exercised at any time within a period of 18 months from the date of allotment of Warrants, in one or more tranches as the case may be and on such other terms and conditions as applicable. In case the investor fails to exercise the same within the stipulated period, the warrants shall lapse.</p> <p>*The issuance of Convertible Warrants is subject to the approval of members by way of passing special resolution at the Extra Ordinary General Meeting to be held on February 03, 2025.</p>



AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Phone: 0172-5020758-69 Website: www.ajoonibiotech.com

E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

LIST OF INVESTORS FOR CONVERTIBLE WARRANTS:

Sl. No.	Name	Category	No. of Warrants
1.	Jasjot Singh	Promoter	1,00,00,000
2.	Healthy Biosciences Limited	Promoter	1,00,00,000
3.	Al Maha Investment Fund PCC	Non-Promoter	90,00,000
4.	Minerva Ventures Fund	Non-Promoter	90,00,000
5.	Veer Energy & Infrastructure Limited	Non-Promoter	90,00,000
6.	Gala Finance and Investment Private Limited	Non-Promoter	10,00,000
7.	Sangita Tundiya	Non-Promoter	20,00,000
Total			5,00,00,000

ANNEXURE B

BRIEF PROFILE OR MR. ISHTNEET BHATIA

<u>S.NO.</u>	<u>PARTICULARS</u>	<u>INFORMATION</u>
1.	Type of event	Appointment of Mr. Ishtneet Bhatia as an Independent Director subject to approval of the members at the ensuing General Meeting
2.	Date of Birth	19/12/1991
3.	Date of Appointment on the Board	03 rd January 2025
4.	Nationality	Indian
5.	Category	Independent Non- Executive Director
6.	Qualification	Bachelor of Laws
7.	Brief Profile/ Expertise	He holds more than 6 years of experience as an Advocate and 7 years of experience as a Corporate Legal Advisor. Wide experience in handling all types of Corporate Recovery matters, RERA, Consumer Commission, NCLT, etc. He has also represented Govt. Departments like GMADA, ADA, JDA, various real estate companies as well.
8.	List of other listed companies in which Directorship is held as on 31/12/2024	Nil
9.	Chairman/ Member of The Committee of the Board Of the Other Companies in which he is a director as on 31/12/2024	Nil
10.	Equity Shares held in the Company as on 31/12/2024	NIL
11.	Disclosure of relationships between existing directors and new director	Not related to any director